Holen Sie sich die Stockscreener-App
4.37
0.23%
0.010
Handel nachbörslich:
4.37
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals stock trades at USD 4.10 - AD HOC NEWS
Verrica Pharmaceuticals stock holds steady as investors watch latest clinical and earnings signals - AD HOC NEWS
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals stock holds steady as investors look to lead product progress - AD HOC NEWS
VRCA: Phase III programs for common warts and BCC advance rapidly, with strong efficacy and global expansion - TradingView
Verrica Pharmaceuticals at H.C. Wainwright conference: growth and pipeline By Investing.com - Investing.com Canada
Verrica Puts Investor Focus on Dermatology Pipeline - MyChesCo
Net current asset value per share of Verrica Pharmaceuticals Inc. – HAM:1NE0 - TradingView
Number of shareholders of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - tradingview.com
Number of shareholders of Verrica Pharmaceuticals Inc. – HAM:1NE0 - TradingView
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - marketscreener.com
Verrica Pharmaceuticals Inc. Balance Sheet – HAM:1NE0 - TradingView
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
A contagious skin infection affects about 6 million, mostly children. Verrica presents Sept. 14. - Stock Titan
Verrica Pharmaceuticals Stock Price Forecast. Should You Buy VRCA? - StockInvest.us
Verrica Pharmaceuticals Inc. (VRCA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills - MyChesCo
Verrica Pharmaceuticals (VRCA) Drops 4% to $5.46 as Support Level Comes into FocusIPO Entry Watch - siam.in
Breakout Bulletin: August 24-August 28 - Dermatology Times
Verrica completes enrolment in Phase III trial of Ycanth - Clinical Trials Arena
Technical Analysis on One NASDAQ- Listed Pharmaceuticals Stock: VRCA - kalkine.com.au
Verrica Completes Enrollment in Phase 3 YCANTH Common Warts Trial - Dermatology Times
VRCA Looks 46.0% Undervalued on GF Value™ Despite Speculative Ri - GuruFocus
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027 - Yahoo Finance
Verrica (VRCA) Results Versus Estimates: The Bottom-Line Figure Trails Its Comparison in the Current Update; Share Move: Shares Move 1.04% Up at the CloseEarnings Miss Streak - dars.gov.et
Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current SessionGuidance Revision Trend - vinanet.vn
Verrica (VRCA) Update: Closes 0.82% Lower at $4.82 for the Current Session; Technical Setup: the Near-Term Reference Band Stretches From $4.58 to $5.06 on the DayHigh Volume Node - dars.gov.et
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Verrica (VRCA) Financial Results: EPS Misses Its Estimate in Latest Trading; Trading-Day Reaction: Shares Move 4.29% Lower on the DayReturn On Capital - vinanet.vn
Verrica Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares - MarketBeat
Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy - Stock Titan
Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August - Stock Titan
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals Inc (VRCA) (Q2 2026) Earnings Call Highl - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade PersistsAdvance Decline Volume - dars.gov.et
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison - TradingKey
Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary - TradingView
Verrica secures $27.5 million credit facility from chairman - Investing.com
Verrica Reports Q2 Revenue of $5.9 Million as YCANTH Demand Rises - Quiver Quantitative
Verrica Pharmaceuticals reports Q2 2026 revenue $5.9M, net loss $13.2M; YCANTH demand up - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Q2 FY2026 earnings call transcript - Yahoo Finance
Verrica Pharma reports wider-than-expected Q2 adj loss per share - TradingView
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - The Manila Times
YCANTH applicator units reach 19,626; common-wart data expected mid-2027 - Stock Titan
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):